GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug

GARDP and Swiss biopharmaceutical company Debiopharm have signed a collaboration and license agreement to jointly advance Debio1453, a novel first-in-class antibiotic targeting Neisseria gonorrhoeae, in response to the global surge in multidrug-resistant gonorrhea that now threatens the effectiveness of existing treatments. Under the partnership, Debiopharm will complete the Phase I trial while GARDP leads further clinical/non-clinical development and aligns regulatory and access strategies, with manufacturing and commercialization rights granted to GARDP in over 160 countries to support broad global access and help ensure gonorrhea remains a treatable disease.